dacarbazine medac 1 000 mg inj. sol. (pwdr.) i.v. vial
medac gmbh - dacarbazine citrate 1350 mg - eq. dacarbazine 1000 mg - powder for solution for injection - 1000 mg - dacarbazine citrate 1350 mg - dacarbazine
dacarbazine medac 500 mg inj. sol. (pwdr.) i.v. vial
medac gmbh - dacarbazine citrate 675 mg - eq. dacarbazine 500 mg - powder for solution for injection - 500 mg - dacarbazine citrate 675 mg - dacarbazine
dacarbazine medac
medac gmbh - dacarbazine - powder for solution for injection or infusion - 200mg
dacarbazine sandoz
sandoz pty ltd - dacarbazine -
dacarbazine for injection bp powder for solution
pfizer canada ulc - dacarbazine - powder for solution - 600mg - dacarbazine 600mg - antineoplastic agents
dacarbazine - dacin 200 mg
propharm ltd - dacarbazine - powder for solution for inj/inf - dacarbazine 200 mg/vial - other alkylating agents - for the treatment of metastatic malignant melanoma, hodgkin's disease as a second line therapy when used in combination with other agents.
dbl dacarbazine 200mg powder for injection
pfizer australia pty ltd - dacarbazine, quantity: 200 mg - injection, powder for - excipient ingredients: mannitol; citric acid monohydrate - chemotherapy of metastatic malignant melanoma and various sarcomas. in other cancers, the available evidence shows dacarbazine to be ineffective or less effective than established regimens. note: the use of dacarbazine is restricted to hospitals with an oncology service.
dacarbazine injection, powder, for solution
meitheal pharmaceuticals inc. - dacarbazine (unii: 7gr28w0fji) (dacarbazine - unii:7gr28w0fji) - dacarbazine for injection is indicated in the treatment of metastatic malignant melanoma. in addition, dacarbazine for injection is also indicated for hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. dacarbazine for injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.
dbl™ dacarbazine
pfizer new zealand limited - dacarbazine 200mg; ; - powder for injection - 200 mg - active: dacarbazine 200mg excipient: citric acid monohydrate mannitol - chemotherapy of metastatic malignant melanoma and various sarcomas. in other cancers, the available evidence shows dacarbazine to be ineffective or less effective than established regimens.
dacarbazine medac
medac gmbh - dacarbazine - powder lyophilized for solution for injection - 100mg